Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹53 Cr.
Stock P/E
12.4
P/B
0.6
Current Price
₹3
Book Value
₹ 5.2
Face Value
2
52W High
₹5.5
52W Low
₹ 2.7
Dividend Yield
0%

Ajooni Biotech Overview

Business

Ajooni Biotech Ltd. is an Indian company primarily engaged in the manufacturing and selling of various types of animal feed. Its core business model involves producing compound feed products, such as cattle feed, poultry feed, and potentially feed for other livestock or aquaculture, using a mix of agricultural raw materials and supplements. The company generates revenue by selling these feed products directly to farmers, dairy owners, poultry farms, and through a network of distributors. The aim is to provide nutritious and balanced feed to improve animal health, productivity, and yield for its customers.

Revenue Mix

The company's primary revenue stream is derived from the sale of animal feed products. While specific sub-segment contributions are not publicly available, it likely includes:

Cattle Feed: For dairy and beef cattle.

Poultry Feed: For broiler and layer chickens.

Given its industry focus, a vast majority, if not all, of its revenue comes from the animal feed segment.

Industry

The Indian animal feed industry is characterized by a mix of organized national players and numerous regional and local manufacturers. It is a growing sector driven by increasing demand for animal protein, professionalization of livestock farming, and a shift towards compound feed. Ajooni Biotech Ltd. likely operates as a regional player, competing with both larger established companies that have national distribution networks and other local manufacturers. Its positioning would depend on its geographical presence, product specialization, and pricing strategy within specific states or districts in India.

MOAT

Ajooni Biotech Ltd. is likely to have a limited competitive moat.

Brand: It may have established some regional brand recognition and loyalty among local farmers, but it is unlikely to possess a strong national brand moat against larger players.

Scale: While it might achieve some economies of scale within its operating regions, it likely doesn't have a significant scale advantage over large national competitors.

Distribution Network: A well-established local/regional distribution network and strong relationships with farmers and distributors could provide a minor advantage.

Switching Costs: Switching costs for farmers are generally low, as many feed products are interchangeable unless specific formulations offer demonstrably superior results.

Overall, competitive advantages are likely to be moderate, relying on product quality, pricing, and localized customer service.

Growth Drivers

Rising Demand for Animal Protein: India's growing population and increasing disposable incomes are fueling higher consumption of milk, eggs, and meat, consequently driving demand for animal feed.

Professionalization of Farming: A shift from traditional subsistence farming to commercial dairy, poultry, and aquaculture operations increases the demand for scientifically formulated, high-quality compound feed.

Government Support: Initiatives to boost the livestock and dairy sectors often provide a conducive environment for feed manufacturers.

Product & Geographical Expansion: Expanding the product portfolio to include new feed types (e.g., aquaculture feed) or increasing geographical reach can drive growth.

Improved Feed Efficiency: Farmers' increasing awareness about the economic benefits of better feed for higher yields and animal health.

Risks

Raw Material Price Volatility: Key inputs such as grains (maize, soy), oilseed meals, and other supplements are agricultural commodities subject to price fluctuations due to weather, government policies, and global supply-demand dynamics.

Intense Competition: The industry is highly competitive, leading to pricing pressures and potential erosion of margins from both large organized players and local unorganized manufacturers.

Disease Outbreaks: Outbreaks of animal diseases (e.g., bird flu, African Swine Fever) can severely impact livestock populations and, consequently, the demand for feed.

Regulatory Changes: Changes in regulations regarding feed quality, ingredients, or environmental norms can impact production costs and processes.

Weather Dependence: Adverse weather conditions can affect crop yields, impacting raw material availability and prices.

Credit Risk: Dependence on timely payments from farmers and distributors, especially in agricultural cycles.

Management & Ownership

Ajooni Biotech Ltd. is typically promoted and managed by its founding family, a common structure for many small and mid-sized companies in India. The vision, experience, and leadership quality of the promoters play a crucial role in the company's strategic direction and execution. Ownership is likely promoter-dominated, with public shareholders holding the remainder. The management team would typically include a mix of family members and professional managers overseeing operations, sales, and finance.

Outlook

Ajooni Biotech operates in a fundamentally growing sector driven by India's demographic and economic trends, particularly the increasing demand for animal protein. This provides a tailwind for the company's core business. The professionalization of farming practices also supports a shift towards organized compound feed. However, the business faces significant challenges including intense price competition, volatility in raw material costs, and the inherent risks associated with livestock farming such as disease outbreaks. The ability of Ajooni Biotech to manage raw material sourcing efficiently, expand its distribution network, maintain product quality, and potentially diversify its product offerings will be critical for sustained growth and profitability in a competitive and cyclical industry.

Ajooni Biotech Share Price

Live · NSE · Inception: 2010
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Ajooni Biotech Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 20 26 26 34 29 31 32 59 59 63
Other Income 0 0 0 0 1 1 0 0 0 0
Total Income 20 26 26 34 31 32 32 59 59 64
Total Expenditure 18 25 25 33 28 31 30 56 56 62
Operating Profit 2 1 1 1 2 1 2 3 3 2
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 1 1 1 2 1 1 2 2 1
Provision for Tax 1 0 0 0 0 0 0 1 1 0
Profit After Tax 1 0 1 1 2 1 1 2 2 0
Adjustments 0 0 0 -0 0 0 0 0 0 -0
Profit After Adjustments 1 0 1 1 2 1 1 2 2 0
Adjusted Earnings Per Share 0.1 0 0 0 0.1 0 0.1 0.1 0.1 0

Ajooni Biotech Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 13 29 42 40 40 51 74 74 80 115 182 213
Other Income 0 0 0 0 0 0 0 0 2 2 2 0
Total Income 13 29 43 40 40 51 74 75 82 117 185 214
Total Expenditure 13 28 41 39 39 49 71 72 78 111 176 204
Operating Profit 0 1 1 1 1 2 3 3 4 6 9 10
Interest 0 0 0 0 0 1 1 0 1 0 1 0
Depreciation 0 0 0 0 0 1 1 1 1 1 2 3
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 0 1 1 2 3 4 6 6
Provision for Tax 0 0 0 0 0 0 0 0 1 1 1 2
Profit After Tax 0 0 0 0 0 0 1 1 2 3 4 5
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 0 0 0 0 0 1 1 2 3 4 5
Adjusted Earnings Per Share 0.3 0.5 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.3 0.3

Ajooni Biotech Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 1 1 11 12 16 16 16 42 43 88 91
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 1 0 4 1 2 3 2 2 1 1
Other Non-Current Liabilities -0 3 2 -0 -0 -0 -0 -0 -0 -0 -0
Total Current Liabilities 2 8 6 2 6 10 10 15 3 5 28
Total Liabilities 2 13 19 18 23 28 29 58 47 95 120
Fixed Assets 0 1 1 1 2 4 6 6 10 11 26
Other Non-Current Assets 0 6 7 5 3 3 1 17 5 21 19
Total Current Assets 2 6 11 12 18 21 22 35 32 62 74
Total Assets 2 13 19 18 23 28 29 58 47 95 120

Ajooni Biotech Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 0 0 5 1 0 0 0 0 0 7
Cash Flow from Operating Activities -1 0 0 -5 -4 1 4 -6 23 -32 -6
Cash Flow from Investing Activities -0 0 0 1 0 -3 -2 -16 8 14 -16
Cash Flow from Financing Activities 1 0 0 -1 3 2 -2 22 -4 25 15
Net Cash Inflow / Outflow -0 0 0 -5 -1 0 -0 0 27 6 -6
Closing Cash & Cash Equivalent 0 0 0 1 0 0 0 0 27 7 0

Ajooni Biotech Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 0.27 0.55 0.12 0.12 0.07 0.07 0.21 0.13 0.25 0.2 0.25
CEPS(Rs) 0.47 0.93 0.22 0.25 0.18 0.19 0.4 0.24 0.35 0.26 0.38
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 1.45 1.92 3.19 3.43 3.34 3.1 3.27 4.76 4.87 5.09 5.27
Core EBITDA Margin(%) 1.74 2.34 2.19 1.78 3.02 3.23 3.96 3.71 2.79 3.22 3.43
EBIT Margin(%) 1.22 1.84 1.97 1.53 2.02 2.13 2.7 2.76 4.43 4.07 3.55
Pre Tax Margin(%) 1.07 1.36 1.15 1.2 1.2 0.99 1.97 2.12 3.74 3.77 3.15
PAT Margin (%) 0.73 0.97 0.91 1.03 0.87 0.73 1.42 1.51 2.7 2.94 2.37
Cash Profit Margin (%) 1.27 1.64 1.65 2.14 2.1 1.86 2.73 2.86 3.79 3.89 3.58
ROA(%) 4.78 3.61 2.4 2.2 1.69 1.47 3.7 2.58 4.09 4.75 4.03
ROE(%) 20.38 36.98 6.8 3.72 2.54 2.4 6.58 3.87 5.12 5.18 4.84
ROCE(%) 18.62 36.19 10.03 3.84 4.35 5.07 9.09 5.99 7.75 6.94 6.53
Receivable days 27.7 16.1 17.94 35.36 79.67 94.23 67.91 84.26 76.34 46.43 34.07
Inventory Days 10.6 29.6 26.78 32.48 38.09 30.97 27.75 31.55 50.94 62.62 63.48
Payable days 31.05 45.37 29.93 10.48 16.19 31.11 34.78 46.94 30.34 9.55 15.31
PER(x) 0 0 37.96 23.11 14.32 63.36 49.93 27.12 21.09 28.6 15.3
Price/Book(x) 0 0 1.41 0.81 0.32 1.52 3.2 0.73 1.07 1.1 0.73
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.07 0.03 0.43 0.41 0.28 0.72 0.98 0.53 0.67 0.8 0.46
EV/Core EBITDA(x) 4.07 1.19 15.86 15.57 8.68 22.19 24.44 12.9 12.07 15.91 9.62
Net Sales Growth(%) 83.46 115.71 48.51 -6.27 0.79 27.49 45.06 0.61 7.55 43.16 59.02
EBIT Growth(%) 50.37 224.98 59.38 -27.43 33.45 34.59 83.88 2.69 72.89 31.26 38.69
PAT Growth(%) 32.55 185.79 40 6.45 -15.62 7.57 181.14 7.24 92.16 56.02 28.18
EPS Growth(%) 32.55 103.17 -78.26 1.26 -38.2 0.44 180.97 -38.74 92.13 -20.63 28.14
Debt/Equity(x) 1.5 0.64 0.45 0.41 0.32 0.44 0.33 0.12 0.05 0.02 0.2
Current Ratio(x) 1.25 0.73 1.87 6.14 3 2.05 2.18 2.28 10.74 11.31 2.67
Quick Ratio(x) 1 0.22 1.56 3.54 2.43 1.53 1.6 1.82 5.63 6.94 1.26
Interest Cover(x) 7.94 3.84 2.41 4.63 2.47 1.86 3.71 4.3 6.38 13.95 8.87
Total Debt/Mcap(x) 0 0 0.25 0.39 0.79 0.22 0.08 0.15 0.04 0.02 0.27

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +58% +35% +29% +30%
Operating Profit CAGR +50% +44% +35% —
PAT CAGR +33% +59% — —
Share Price CAGR -43% -8% -21% —
ROE Average +5% +5% +5% +9%
ROCE Average +7% +7% +7% +10%

Ajooni Biotech Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 30.53 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 69.47 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 26.8926.8926.8926.8926.8926.8926.8926.8926.8930.53
FII 00.290.180000000
DII 0000000000
Public 73.1172.8272.9273.1173.1173.1173.1173.1173.1169.47
Others 0000000000
Total 100100100100100100100100100100

Ajooni Biotech Peer Comparison

Animal Feed Edit Columns

Ajooni Biotech Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Ajooni Biotech Pros & Cons

Pros

  • Stock is trading at 0.6 times its book value
  • Company is almost debt free.

Cons

  • Promoter holding is low: 30.53%.
  • Company has a low return on equity of 5% over the last 3 years.
  • Debtor days have increased from 9.55 to 15.31days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp